Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To characterize the pharmacokinetics and safety of buparlisib following a single 50 mg oral
dose in subjects with moderate and severe renal impairment.